Is measurable residual disease (MRD) ready for prime time in multiple myeloma (MM)? Gareth Morgan, MD, PhD, FRCP, FRCPath, of UAMS Myeloma Institute, Little Rock, AR, chairs a discussion with Jens Lohr, MD, PhD, of the Dana-Farber Cancer Institute, Boston, MA, Angela Dispenzieri, MD, of the Mayo Clinic, Rochester, MN, Ola Landgren, MD, PhD, of the Memorial Sloan Kettering Cancer Center, New York, NY. Speaking from the Myeloma 2018 meeting, held in San Diego, CA, the experts discuss this exciting topic.
Is MRD testing ready for prime time in myeloma?
